Arap W, Pasqualini R, Ruoslahti E
Cancer Research Center, Burnham Institute, La Jolla, CA 92037, USA.
Curr Opin Oncol. 1998 Nov;10(6):560-5. doi: 10.1097/00001622-199811000-00014.
Vasculature-targeted chemotherapy--the destruction of tumor blood vessels with cytotoxic agents--makes use of biochemical differences between angiogenic and resting blood vessels. This approach may minimize or eliminate some of the problems associated with conventional solid-tumor targeting, such as poor tissue penetration and drug resistance. Experiments with antiangiogenic and thrombotic factors have shown that eliminating tumor blood supply has dramatic antitumor effects in mice. Targeting chemotherapeutic agents to the tumor vasculature combines the blood vessel destruction with the usual antitumor activities of the drug, resulting in increased efficacy and reduced toxicity in experiments with tumor-bearing mice. Human clinical trials, which are soon to follow, will determine the final value of this approach.
血管靶向化疗——用细胞毒性药物破坏肿瘤血管——利用了生成血管的血管与静止血管之间的生化差异。这种方法可能会减少或消除一些与传统实体瘤靶向治疗相关的问题，如组织穿透性差和耐药性。抗血管生成和血栓形成因子的实验表明，消除肿瘤血液供应在小鼠中具有显著的抗肿瘤作用。将化疗药物靶向肿瘤血管，将血管破坏与药物通常的抗肿瘤活性相结合，在荷瘤小鼠实验中提高了疗效并降低了毒性。即将开展的人体临床试验将确定这种方法的最终价值。
